OTC Markets:MATN

AGOURA HILLS, California, Jan. 25, 2021 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced that it will be launching its mobile app, ARTIHealthTM, for respiratory health assessment, in India along with its COVID-19 therapeutic, PulmoHealTM also known as ARTIVedaTM, for total care of COVID-19 patients. Published on : http://www.globenewswire.com/news-release/2021/01/25/2163368/0/en/MATEON-LAUNCHING-MOBILE-APP-ARTIHEALTH-FOR-REMOTE-RESPIRATORY-HEALTH-ASSESSMENT.html…

More

AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) — Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive interim results from its ARTI-19 clinical trial evaluating ARTIVedaTM against COVID-19. Published on : http://www.globenewswire.com/news-release/2021/01/13/2157767/0/en/MATEON-ANNOUNCES-POSITIVE-INTERIM-RESULTS-FROM-ARTI-19-CLINICAL-TRIAL-EVALUATING-COVID-19-THERAPEUTIC.html…

More

-FPI FOR C001 PHASE 2 TRIAL AGAINST COVID-19 Published on : http://www.globenewswire.com/news-release/2020/12/30/2151812/0/en/MATEON-S-GLOBAL-STUDY-FOR-OT-101-TGF-%CE%B2-INHIBITOR-AGAINST-COVID-19-ENROLLS-AND-TREATS-ITS-FIRST-PATIENT.html…

More